Joaquin Duato $JNJ SEC Form 4 Insider Trading

Joaquin Duato has filed a total of 5 insider trades in $JNJ since 2021. Their most recent trade was a sale of 41,957 shares, made on Aug 05, 2026. Their largest trade was a sale of 125,824 shares, made on Aug 22, 2025. We estimate that they now own 313,342 shares of $JNJ, worth an estimated $91.3 million.

Insider Trading at $JNJ

There have been a total of 379 insider trades reported at $JNJ since 2021, with 2,250 shares purchased and 1.3 million shares sold. The most active insider traders in $JNJ stock have been Peter Fasolo, Thibaut Mongon, and William Hait. The most recent trade was a sale of 6,523 shares reported by Joaquin Duato (CEO and Chairman of the Board), made on Aug 05, 2026.

$JNJ Executives and Stock Owners with Insider Trades

• Peter Fasolo, Exec VP, Chief HR Officer

• Thibaut Mongon, Exec VP, WW Chair, Consumer

• William Hait, See Remarks

• Joseph J Wolk, Exec VP, CFO

• Joaquin Duato, CEO and Chairman of the Board

• Kathryn E Wengel, EVP, Chief GSC Officer

• John C Reed, EVP, Innovative Medicine, R&D

• Timothy Schmid, EVP, WW Chair, MedTech

• James D. Swanson, EVP, CIO

• Robert J Decker, Controller, CAO

• Robert J Decker, VP Corporate Controller

• Vanessa Broadhurst, EVP, Global Corp Affairs

• Jennifer L Taubert, EVP, WW Chair, Pharmaceuticals

• Elizabeth Forminard, EVP, Chief Legal Officer

• Kathryn E Wengel, EVP, Chief TO and Risk Officer

• Ashley Mcevoy, EVP, WW Chair, MedTech

• Jennifer L Taubert, EVP, WWC. Innovative Medicine

• James D. Swanson, See Remarks

*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.